Shares of DraftKings cratered 21% to $18.56 in pre-market trading after the company delivered a Q3 miss on nearly every metric and slashed its outlook — forcing Wall Street to reconsider how long the road to profitability really is.

• The Quarter Was Worse Than Anyone Modeled

DraftKings posted a non-GAAP loss of $0.53 per share, missing estimates by $0.28.

Revenue came in at $1.329 billion, up 16% year-over-year but $69 million below the Street's $1.398 billion consensus.

Adjusted EBITDA swung to a loss of $316.9 million, compared with a $126.5 million loss a year ago.

Analysts had expected a far narrower EBITDA loss of roughly $49 million — meaning the actual shortfall was more than six times what was priced in.

• Prediction Markets Are Eating the Profit Line The culprit is clear: DraftKings' push into prediction markets — a product that lets users trade on the outcomes of sports and other events — is absorbing enormous capital. Management now expects 2026 adjusted EBITDA of just $175 million to $275 million, down from a prior range of $700 million to $900 million.

The prediction-markets business alone is expected to reduce 2026 EBITDA by $650 million to $700 million.

Revenue from the product will be "immaterial" in 2026, as new-customer promotions offset gross revenue.

• The 2027 Outlook Fell Short of the Bar Wall Street Set

DraftKings guided to 2027 revenue of $7.35 billion to $7.75 billion and adjusted EBITDA of $800 million to $1.0 billion.

Analysts had been modeling about $1.12 billion in 2027 EBITDA — meaning even the top end of guidance falls short. Management expects core sports betting and casino revenue of $6.7–$7.0 billion, with prediction-markets revenue of $650–$750 million.

• The Valuation Case Now Hinges on a Product That Hasn't Proved Itself

DraftKings trades at a price-to-sales ratio of roughly 1.9x, well below its historical median of about 4.2x , reflecting deep skepticism. More than 1.6 million customers have engaged with predictions year-to-date, and management claims an approximately 20-month payback period on the 2026 cohort. But investors must now trust that hundreds of millions in spending will convert into real earnings — while competitors and regulators circle the same market. Until that proof arrives, the stock trades like the bet it's asking shareholders to make.